Can immunotherapy stop and prevent autoimmune disorders?Are you ready?
- Immunotherapy development landscape and regulation
- Global immunotherapy players
- Immunotherapy for diabetes type
- Research Spotlight with a biotech R&D Director at Imcyse
Event details
|
DATE Wednesday July 22, 2020 VENUE Online Webex / Gotomeeting TIME 10am -11am (Berlin time) 4:00 PM - 5:00 PM (Beijing time) RSVP This is a complimentary event VIP tickets priority for Lingmed current clients Please RSVP by July 21, 2020 |
PRESENTERS Lingling Cao, CEO & Founder Dr Hank Wang, Medical advisor Dr Luc Vander Elst, R&D Director, In Vivo and Imotope Development REGISTER +86 21 5386 3003 info@lingmed.net |
Agenda
| CET 10:00 - 10:30 | Immunotherapy development landscape and regulation Global immunotherapy players Immunotherapy for diabetes |
by Dr Hank Wang (Chinese) |
| CET 10:30 - 10:35 | Linkedbio services & projects introductions | by Lingling Cao (English) |
| CET 10:35 - 10:55 | Research Spotlight with Dr Luc Vander Elst, R&D Director at Imcyse | by Dr Luc Vander Elst (English) |
| CET 10:55 – 11:00 | Q&A | (English & Chinese) |
Presenters
 |
Lingling Cao CEO & Founder Lingling has more than a decade of experience in the healthcare industry, especially in deal-making. She founded Lingmed, which aims to support BD professionals to make better decisions with intelligence databases and EU-China cross-border deals. Prior to her venture at Lingmed, she was a senior BD manager for Eli Lilly in Shanghai and a consultant for McKinsey in Germany |
 |
Hank Wang Medical advisor Dr Wang holds a PhD degree on Medicinal Chemistry from Peking University, has a Postdoc experience in University of Missouri-Saint Louis, and worked as a Postdoc Fellow in Auburn University. Hank Wang has more than 10 years’ experience in pharmaceuticals industry. Hank has worked as Vice President and President of R&D at Beijing Haiyan Pharmaceutical Co., Ltd. - Yangtze River Pharmaceutical Group. Dr Wang advises Lingmed on innovative assets evaluation for China market |
 |
Luc Vander Elst R&D Director, In Vivo and Imotope Development Luc Vander Elst has been part of Imcyse’s management team since its inception and worked for over 20 years on the Company’s technology. He is in charge of research and development management, Imotope™ design and development as well as preclinical research and development. Luc holds an Engineering degree in Chemistry option Biochemistry and an M.Sc. in Immunology and genetic from the Catholic University of Leuven (KUL), and worked as a researcher for KUL in the Immunology Group of the Center for Vascular and Molecular Biology which is at the origin of Imcyse’s technology |